NasdaqGM:ANIPPharmaceuticals
Strong 2025 Revenue Guidance Might Change the Case for Investing in ANI Pharmaceuticals (ANIP)
On September 9, 2025, ANI Pharmaceuticals announced new earnings guidance for the year, projecting total revenues between US$818 million and US$843 million, representing estimated growth of 33% to 37% over last year.
This strong projection signals management's confidence in expanded product adoption and suggests a sharply accelerated phase of growth compared to previous years.
We'll explore how this higher-than-expected revenue forecast may shift perspectives on ANI Pharmaceuticals' future...